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Toll-like receptors (TLRs) mediate innate immunity,
and their dysregulation may play a role in -synucle-
inopathies, such as Parkinson’s disease or multiple
system atrophy (MSA). The aim of this study was to
define the role of TLR4 in -synuclein–linked neuro-
degeneration. Ablation of TLR4 in a transgenic mouse
model of MSA with oligodendroglial -synuclein over-
expression augmentedmotor disability and enhanced
loss of nigrostriatal dopaminergic neurons. These
changes were associated with increased brain levels
of -synuclein linked to disturbed TLR4-mediated mi-
croglial phagocytosis of -synuclein. Furthermore, tu-
mor necrosis factor- levels were increased in the
midbrain and associated with a proinflammatory as-
troglial response. Our data suggest that TLR4 ablation
impairs the phagocytic response of microglia to -sy-
nuclein and enhances neurodegeneration in a trans-
genic MSA mouse model. The study supports TLR4
signaling as innate neuroprotective mechanism act-
ing through clearance of -synuclein. (Am J Pathol
2011, 179:954–963; DOI: 10.1016/j.ajpath.2011.04.013)
-Synuclein (AS) cytoplasmic inclusions are the pathologi-
cal hallmark of Parkinson’s disease (PD), dementia with
Lewy bodies (DLB), and multiple system atrophy (MSA)
commonly called -synucleinopathies (ASPs). It is currently
accepted that AS plays a major role in the pathogenesis of
these disorders as suggested by genetic1–3 and experi-
mental studies on the toxicity of AS species.4–14 Recent
observations showed up-regulation of Toll-like receptors
(TLRs) in ASPs,15,16 but their contribution to the pathogen-
esis has not been studied. TLRs are a family of highly
conserved molecules that recognize pathogen-associated
molecular patterns, including both exogenous and endog-
954enous ligands, and define the innate immunity response.17
In the central nervous system different types of TLRs have
been identified up-regulated in response to systemic or
local insults.18 TLR4 is associated with CD14-mediated li-
popolysaccharide-induced inflammatory signaling, and
several observations suggest its role in ischemic brain dam-
age.19,20 TLR2 and TLR4/CD14 complex have been asso-
ciated with the removal of amyloid-, indicating innate im-
munity receptors on microglia as a natural defense
mechanism to prevent amyloid- accumulation.21–24
Several models of both neuronal25 and oligodendro-
glial26 ASPs have been developed using targeted over-
expression of AS. The proteolipid protein (PLP) human
AS (hAS) mouse model represents a model of MSA-like
neuropathology with oligodendroglial AS aggregates27
associated with progressive microglial activation and ni-
gral degeneration.15 This model provides a suitable test
bed to address questions related to AS-induced neuro-
inflammatory responses and neurodegeneration.
The main objective of the current study was to determine
the role of TLR4 ablation on motor disability and neuronal
loss in the PLP transgenic mouse model of ASPs. We used
behavioral, morphologic, biochemical, and cell culture as-
says to analyze the effect of TLR4 deficiency. TLR4 defi-
ciency was associated with suppression of microglial AS
phagocytosis, resulting in poor AS clearance and acceler-
ated neurodegeneration in the ASP model.
Materials and Methods
Transgenic Mouse Lines
Homozygous AS transgenic mice harboring the hAS un-
der the control of the PLP promoter27 were cross-bred
with TLR4/ mouse strain (C57BL/10ScNJ with a dele-
tion of the TLR4 gene), so that they fail to express TLR4
mRNA and protein,28 to get first-generation heterozygous
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double-heterozygous mice were further bred to generate
in the second-generation AS-expressing TLR4-deficient
mice (either AS/,TLR4/ or AS/,TLR4/). To se-
lect for the double-homozygous line, AS-expressing
TLR4-deficient mice were bred for at least three further
generations, and only families with 100% AS-expressing
TLR4-deficient offspring were kept. All mice were geno-
typed by tail clip using two subsequent PCR reactions for
hAS (controlled versus mouse connexin 32) and mouse
TLR4 (controlled versus mouse AS) using the primers
indicated in Table 1. The generation of the PLP-AS mouse
was previously described.27 Homozygous PLP-AS trans-
genic mice were initially provided by Philipp Kahle, Munich,
Germany, and further bred at the Animal Facility of Inns-
bruck Medical University. Homozygous C57BL/10ScNJ
mice28 were purchased at Jackson Laboratories (stock No.
003752) and further bred at the Animal Facility of Innsbruck
Medical University. All experiments were performed ac-
cording to the Austrian law and with permission by the
Federal Ministry for Science and Research of Austria. Ani-
mals were housed under a 12-hour light/dark cycle with
food and water available ad libitum. All efforts were made to
minimize the number of animals used and their suffering.
Phenotypic characterization of mice overexpressing
hAS with normal TLR4 expression (assigned here as
AS,TLR4/) and mice with overexpression of hAS and
TLR4 deficiency (assigned here as AS,TLR4/) was per-
formed at 6 months of age. To collect brain tissue, mice
were deeply anesthetized via an i.p. injection of thiopen-
tal and then perfused intracardially with PBS followed by
ice-cold 4% paraformaldehyde in PBS, pH 7.4. Brains
were rapidly removed from skulls, postfixed overnight in the
same fixative at 4°C, and cryoprotected in 25% sucrose in
PBS. Frozen brains were cut serially (40-m-thick sections)
using a cryostat (Leica, Nussloch, Germany).
For protein analysis, mice were anesthetized with thio-
pental and perfused intracardially with PBS to remove
blood from organs, brains were quickly removed, and
blocks of forebrain and midbrain were dissected, snap
frozen in liquid nitrogen, and finally stored at 80°C.
Probes were homogenized on ice in lysis buffer contain-
ing Complete Mini Protease Inhibitor Cocktail (Roche Ap-
plied Science, Indianapolis, IN), protein concentration
was measured by bicinchoninic acid protein assay (Sigma-
Aldrich, St. Louis, MO), and aliquots for further analysis
Table 1. Primer Pairs and Product Sizes Used for Genotyping
Gene Product size, bp
Human AS 450
Mouse CX32 831
Mouse TLR4 415
Mouse AS 760
CX32, connexin 32; Fwd, forward; Rev, reverse.were stored at 80°C.Behavioral Analyses
The behavioral experimenter was masked to the genetic
status of the animals. To test locomotor disability, mice were
tested in a pole test and an open field test. In the first
paradigm we evaluated the ability of each mouse to climb
down a vertical wooden pole with a rough surface, 1 cm
wide and 50 cm high, as a measure of bradykinesia, bal-
ance, and coordination. Each mouse was placed with the
head up at the top of the pole, and the time for turning
downwards and the total time for climbing down the pole
until the mouse reached the floor with the four paws were
taken in five trials. The best performance of each mouse
was kept for the statistical analysis.29,30 In the second par-
adigm, spontaneous locomotor activity within a 15-minute
interval in an open field arena was measured by Flex Field
Activity System (San Diego Instruments, San Diego, CA),
which allowsmonitoring and real-time counting of horizontal
and vertical locomotor activity by 544 photo-beam chan-
nels. Mice were placed in the center of the open field
(40.5 40.5 36.5 cm) and tested always at the same time
of the day (6 PM). The tests were performed in a dark room
that is completely isolated from external noises and light
during the test period.30
Neuropathology, Confocal Microscopy, and
Stereologic Analysis
The following primary antibodies were used in this study:
monoclonal mouse antidopamine and cyclic AMP–regu-
lated phosphoprotein (DARPP-32; a generous gift of Prof.
Hugh Hemmings, New York, NY), monoclonal mouse an-
tityrosine hydroxylase (TH; Sigma), monoclonal rat anti-
hAS (15G7; a generous gift of Prof. Philipp Kahle, Tü-
bingen, Germany), monoclonal rat anti-mouse CD11b (Se-
rotec, Oxford, England), monoclonal mouse anti–glial fibril-
lary acidic protein (GFAP; Millipore, Temecula, CA), and
purified anti-mouse tumor necrosis factor (TNF)- (BioLeg-
end, San Diego, CA). Immunohistochemistry (IHC) was
performed according to standard protocols. Shortly, free-
floating sections were treated with 0.3% H2O2 to quench
endogenous peroxidase activity, then permeabilized or
blocked in solution containing 0.1% Triton X-100, 1%
bovine serum albumin, and 10% normal serum (from goat
or horse as appropriate) in PBS. Sections were thereafter
incubated with primary antibody overnight at 4°C, then
Primer pair
Forward: 5=-ATGGATGTATTCATGAAAGG-3=
Reverse: 5=-TTAGGCTTCAGGTTCGTAG-3=
Forward: 5=-GACAGGGTCTCATTATGTAGCCTTA-3=
Reverse: 5=-CTGCGATGCTACAGTATCTCAAGTA-3=
Forward: 5=-GAGATGAATACCTCCTTAGTGTTGG-3=
Reverse: 5=-ATTCAAAGATACACCAACGGCTCTGA-3=
Forward: 5=-CTCAGGGTCGACTGCCTTAG-3=
Reverse: 5=-TGCACTCGAAGAGTCCCTTT-3=incubated with the appropriate secondary antibody (bio-
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tories, Burlingame, CA), followed by Elite ABC complex
(Vector Laboratories), and the reaction was visualized by
3,3=-diaminobenzidine. For immunofluorescence, Alexa
488– or Alexa 594–conjugated anti-rat or anti-mouse IgG
(Jackson Immunoresearch Laboratories/Dianova, Ham-
burg, Germany) was applied.
Three-dimensional stacks were acquired with an SP5
confocal microscope (Leica Microsystems, Wetzlar, Ger-
many) using a HCX PL APO 63x, 1.3 NA glycerol immer-
sion objective. Imaging was performed using excitation
with the 488-nm laser line for Alexa 488 and a 561-nm
laser line for Alexa 594. Fluorescence emission was de-
tected from 492 to 519 nm (Alexa 488) and from 594 to
742 nm (Alexa 594). Images were acquired using the
Leica AF acquisition software version 2.2.1 (Leica Micro-
systems). The stacks were recorded according to the Ny-
quist criteria to allow deconvolution. Pixel sizes were there-
fore chosen as follows: x  43.8 nm, y  43.8 nm, and z 
125.9 nm. Image deconvolution was performed using Huy-
gens Professional software version 3.6.0p2 (Scientific Vol-
ume Imaging, Hilversum, the Netherlands) to improve the
resolution. For the SP5 images, a theoretical point spread
function was then used to deconvolve the data using the
Classical Maximum Likelihood Estimation Algorithm option
of the software. Three-dimensional analysis was performed
using Imaris x64 software version 7.1.0 (Bitplane, Zurich,
Switzerland). Briefly, an isosurface was rendered onto the
Alexa 594–positive cells to define the inner and outer bor-
ders of microglia, whereas spot detection was used to iden-
tify hAS-positive profiles. We then applied a clipping plane
through the cell body and rotated it to view the cellular
interior and thus identified the structures of interest.
Unbiased stereologic analysis was performed as pre-
viously described.31 The number of dopaminergic neu-
rons in substantia nigra pars compacta (SNc) and
GABAergic medium spiny neurons in striatum was esti-
mated by optical fractionator (Nikon E-800 microscope,
Nikon digital camera DXM 1200; Stereo Investigator Soft-
ware, MicroBrightField Europe e.K., Magdeburg, Ger-
many). The density of striatal dopaminergic fibers was de-
termined as previously described.32 Briefly, serial sections
throughout the striatum were captured at constant camera
settings with the above mentioned equipment. TH staining
brightness was measured in striatum (ODstriatum) and cor-
pus callosum (ODbackground) and the density of the striatal
dopaminergic fibers (ODTH) was calculated according to
the following formula: ODTHlog (ODstriatum/ODbackground).
Electron Microscopy
Briefly, as previously described,33 fixed brains were vi-
bratomed at 40 m and sections from transgenic
AS,TLR4/ and AS,TLR4/ age-matched mice were
postfixed in 1% glutaraldehyde, treated with osmium te-
troxide, embedded in epon araldite, and sectioned with
an ultramicrotome (Leica). Grids were analyzed with a
Zeiss OM 10 electron microscope as previously de-
scribed.34 For immunogold labeling, sections were
mounted in nickel grids, etched, and incubated with a
rabbit polyclonal antibody against AS (Millipore, Te-mecula, CA) followed by labeling with a secondary anti-
body tagged with 10-nm Aurion ImmunoGold particles
(1:50; Electron Microscopy Sciences, Fort Washington,
PA) with silver enhancement. A total of 125 microglial
cells were analyzed per condition. Cells were randomly
acquired from three grids, and electron micrographs
were obtained at magnifications of 5000 and 25,000.
Measurement of hAS Concentration by ELISA
Protein extracts from the midbrain and forebrain and super-
natants from wild-type or PLP-AS mouse mixed glial culture
were used to measure the level of hAS protein with an
enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen,
Camarillo, CA) according to the protocol of the manufacturer.
Measurement of Cytokine Levels by
Fluorometric Multiplex Bead–Based
Immunoassay
FlowCytomix analysis, including application of the simplex
kits for mouse TNF-, mouse IL-6, mouse interferon (IFN)-,
mouse granulocyte-macrophage colony-stimulating factor
(GM-CSF), mouse IL-10, and mouse IL-1, as well as the
mouse basic kit (all from BenderSystems, Vienna, Austria),
was performed according to the manufacturer protocol us-
ing protein extracts from the midbrain and forebrain.
Cell Culture
Three experimental approaches were used to define AS
phagocytosis by microglial cells: (1) BV2 microglial cell
line incubated with AS debris, (2) BV2 microglial cell line
incubated with recombinant AS, and (3) primary micro-
glia incubated with recombinant AS.
To demonstrate phagocytosis of AS-containing debris by
BV2 microglia in vitro, we used previously described U373
cells overexpressing hAS.10,14,35 AS-containing cells were
brought into cell suspension of 2 106 cells/mL in Dulbec-
co’s modified Eagle’s medium (DMEM) and then underwent
three consecutive freeze-thaw cycles of 30 minutes at
80°C followed by 15 minutes at 66°C. With this proce-
dure, we achieved 100% cell death as controlled by clas-
sical Trypan blue staining. This AS debris suspension was
kept at 80°C for further phagocytosis experiments. BV2
immortalized microglial cell line36,37 (provided by Prof.
Hubert Kerschbaum, Department of Animal Physiology,
University of Salzburg, Salzburg, Germany) was seeded at
a density of 9  105 per well in a 24-well plate with 1 mL of
DMEM supplemented with 10% fetal calf serum (FCS). A
total of 100 L of the AS debris suspension was added to
the BV2 cells, and after 5 minutes, 2 hours, and 24 hours
image analysis was performed using a DMI4000B Leica
microscope provided with Leica application software and
Digital FireWire Color Camera DFC300 FX (Leica Microsys-
tems).
To confirm AS phagocytosis by BV2 microglia and
define the role of TLR4, BV2 cell cultures were exposed to
3 mol/L recombinant AS with or without functional block-
ing of TLR4 achieved by 30-minute pretreatment of the
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(BioLegend, San Diego, CA). Recombinant wild-type hAS
protein was prepared as follows. Full-length hAS was am-
plified from human spinal cord cDNA (Clontech, Palo Alto,
CA) by PCR as previously described.14 The complete AS
coding sequence was cloned into the prokaryotic expres-
sion vector pET101/D-TOPO (Invitrogen, Lofer, Austria) ac-
cording to the manufacturer’s instructions. After sequence
analysis, protein expression was induced using isopropyl-
-thiogalactopyranoside (Sigma-Aldrich). The protein was
purified by affinity chromatography applying nickel ni-
trilo-triacetic acid agarose (Qiagen, Hilden, Germany)
and dialyzed against PBS, pH 7.4. Endotoxin contami-
nation was removed by a Detoxi-Gel endotoxin removing
gel step (Pierce, Rockford, IL) and probes were stored at
80°C.
To confirm AS phagocytosis in primary microglia in rela-
tion to TLR4 expression, purified microglial cell culture from
wild-type and TLR4-deficient newborn mouse brains (days
1 to 3) was prepared. After removal of the meninges, corti-
ces were minced and cells were dissociated with 0.004%
DNase at 37°C and suspended in DMEM:Nutrient MixtureF-12 (DMEM/F12; Gibco Products, Invitrogen Corporation,
Carlsbad, CA) supplemented with L-glutamine, 10%
FCS, 100 U/mL of penicillin, and 100 g/mL of strepto-
mycin. Cells were plated at a density of two brains per
T75 culture flask and incubated at 37°C in a humid at-
mosphere with 5% CO2. Culture medium was changed
twice a week. After 14 days, confluent mixed glial cul-
tures were shaken at 180 rpm on an orbital shaker over-
night at 37°C. Microglial cells in the supernatant after
shaking (90% CD11b positive and 72% TLR4 positive as
measured by flow cytometry, data not shown) were re-
plated in 24-well cell culture plates at a density of 100 000
cells per well in DMEM supplemented with 10% FCS and
L-glutamine. Microglial cultures were exposed to 3
mol/L recombinant AS.
To define extracellular release of hAS from oligoden-
droglia overexpressing hAS under the PLP promoter, pri-
mary mixed glial culture from newborn (days 1 to 3)
PLP-AS and control C57Bl/6 mice was prepared as pre-
viously described.38 After removal of the meninges, cor-
tices were minced and cells were dissociated with
0.004% DNase at 37°C and suspended in DMEM/F12
Figure 1. Locomotor deterioration and neuro-
degeneration in AS,TLR4/ mice. A: Quantifi-
cation of vertical (rearing) and horizontal open
field activity in the Flex Field Activity System
shows significant decrease of rearing behavior of
AS,TLR4/ mice versus AS,TLR4/ mice (for
each n  8), whereas at baseline (wild type
indicates without AS overexpression) no signif-
icant difference was detected between TLR4/
mice and TLR4/ mice. B: Pole test revealed
significant increase of the time needed to turn
down on a vertical pole without significant
change in the total time needed to descend the
pole in AS,TLR4/ mice. Again at baseline
(wild type indicates without AS overexpression)
no significant difference was detected between
TLR4/ mice and TLR4/ mice. Data were
analyzed by two-way analysis of variance (with
factors AS overexpression and TLR4 expression)
with the post hoc Bonferroni test. Results are
presented as mean  SEM. C: Quantification of
dopaminergic neurons by optical fractionator
showed significantly augmented neuronal loss
in SNc of AS,TLR4/ mice but no nigral degen-
eration due to TLR4 deficiency only. Data were
analyzed by two-way analysis of variance (with
factors AS overexpression and TLR4 expression)
with a post hoc Bonferroni test. Results are pre-
sented as mean  SEM (for each group n  6).
D: Quantification of nigral neurons performed in
cresyl violet–stained series throughout SNc con-
firmed amplified neuronal loss in AS,TLR4/
compared with AS,TLR4/mice. E: Parallel to the
enhanced nigral neuronal loss in AS,TLR4/
mice, TH optical density (OD) measurement in
striatum indicated significant loss of striatal dopa-
minergic fibers in AS,TLR4/ mice. F: DARPP-32
IHC for striatal medium spiny neurons showed no
significant difference between AS,TLR4/ and
AS,TLR4/ mice. Groups were compared by un-
paired two-tailed t-test. Results are presented as
mean  SEM (for each group n  6). *P  0.05,
**P  0.01, ***P  0.001, and ****P  0.0001.
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U/mL of penicillin, and 100 g/mL of streptomycin. Cells
were plated at a density of two brains per T75 culture
flask and incubated at 37°C in a humid atmosphere with
5% CO2.Statistical Analysis
Results are shown as the mean  SEM, as indicated in
each figure. Student’s t-test for unpaired data or Mann-
Whitney U-test for nonparametric data were used for sta-
Figure 2. Phagocytosis of AS is modulated by
TLR4. A: Genetically modified U373 cells with
AS inclusion pathology as previously de-
scribed10,14,35 were killed by freeze-thaw cycle,
and the resulting suspension of AS debris was
used to treat BV2 immortalized microglia. After
15 minutes of incubation, large AS debris
marked by red fluorescence was observed in the
vicinity of microglia. After 2 hours of incubation,
AS debris was almost completely incorporated
by microglia and small bodies containing AS
(red fluorescence) could be observed in the cy-
toplasm of microglial cells. Scale bar  50 m.
B: Phagocytosis of recombinant AS (labeled with
15G7 antibody) by BV2 microglia was visualized
by Alexa 488 green fluorescence (arrows point
toward labeled vesicular bodies in the microglial
cytoplasm). Preincubation of the BV2 cells with
functional TLR4 antibody resulted in suppres-
sion of AS phagocytosis as evidenced by disap-
pearance of the Alexa 488–labeled vesicular cy-
toplasmic bodies. Main scale bar  50 m, inset
scale bar  10 m. C: Phagocytosis of recombi-
nant AS after 1-hour incubation with primary
mouse microglia (TLR4/ or TLR4/) was vi-
sualized with anti-hAS immunocytochemistry
and Alexa 594 red fluorescence (arrows). Cells
were counterstained with fluorescein isothiocya-
nate–conjugated wheat germ agglutinin (WGA),
and the percentage of phagocyting cells was de-
fined to be 40% in TLR4/ microglia (123 of 300
cells analyzed) and 2% (11 of 514 cells analyzed) in
TLR4/ microglia. Scale bar  10 m.
Figure 3. A: Immunofluorescence for CD11b
(red) and hAS (green) in the brain of
AS,TLR4/ mice revealed punctuate hAS-posi-
tive structures (arrow) in the cytoplasm of
CD11b-positive microglia opposing a hAS-ex-
pressing oligodendrocyte (scale bar  7 m) as
evidenced by double immunofluorescence for
hAS and CNP (2=,3=-cyclic nucleotide 3=-phos-
phohydrolase, an oligodendroglial marker, scale
bar  5 m.). B: In contrast in AS,TLR4/ mice
hAS strictures (arrow) appeared only outside
CD11b-positive microglia (scale bar  15 m).
C: The localization of hAS in microglia of
AS,TLR4/ mice was further confirmed by a
conventional confocal image stack showing hAS
(green) dot (arrow) and CD11b-labeled micro-
glia (red). Below (xz) and right (yz) views
through the depth of the image stack at the
position represented by the white line, demon-
strating hAS-positive punctuate structure en-
gulfed by microglia. D: Advanced interactive
three-dimensional image analysis with isosur-
face reconstruction of a Z-stack of x-y sections
demonstrated hAS (green, arrow) inside a
CD11b-positive microglial cell (red). Section
view in the x- and y-axes was generated by
using the clipping function of Imaris x64 soft-
ware. Scale bar  2 m.
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used for multiple comparisons. Two-way analysis of vari-
ance with a post hoc Bonferroni test was used when two
independent factors were analyzed (eg, genotype and
area or genotype and treatment as indicated in each
figure). P  0.05 was considered statistically significant.
Results
AS-Overexpressing Mice with Deficient TLR4
Exhibit Exacerbated Motor Disability
To evaluate the in vivo effects of TLR4 in a murine model
of ASP, we generated AS-expressing TLR4-deficient
mice (AS,TLR4/) by cross-breeding AS transgenic
mice expressing hAS under the control of the PLP pro-
moter (PLP-AS mice27) with a mouse strain with deletion
of the TLR4 gene.28 We analyzed the locomotion of
AS,TLR4/ mice compared with AS-expressing mice
with normal expression of TLR4 (AS,TLR4/). Motor
analysis of AS,TLR4/ and AS,TLR4/ mice was per-
formed at 6 months of age. Open field activity test
showed impaired rearing behavior of AS,TLR4/ mice
versus AS,TLR4/ (Figure 1A). In the pole test, the time
to turn downwards on a vertical pole was increased in
AS,TLR4/ mice (Figure 1B). In control mice without
expression of hAS, we did not detect locomotor disability
induced by TLR4 deficiency alone (Figure 1).
TLR4 Deficiency in AS-Overexpressing Mice
Augments Neuronal Loss in SNc and Loss of
Dopaminergic Terminals in Striatum
In the control group of TLR4-deficient mice, we found a
preserved number of nigral dopaminergic neurons ver-
sus control wild-type mice (Figure 1C). We have previ-
ously observed a selective susceptibility of nigral dopa-
minergic neurons to oligodendroglial AS overexpression
in the transgenic mouse model applied here.30 We dem-
onstrate now that the deletion of TLR4 in the ASP model
augmented dopaminergic nigral cell loss (Figure 1C) cor-
responding to loss of cresyl violet–stained neurons in
SNc (Figure 1D) and loss of dopaminergic terminals in
the striatum (Figure 1E). However, the number of striatal
DARPP-32–positive GABAergic medium spiny neurons
appeared unaffected by TLR4 deficiency in AS,TLR4/
mice compared with AS,TLR4/ mice (Figure 1F).
TLR4 Deficiency Is Associated with Disturbed
Clearance of AS
Previous in vitro studies suggested microglia as the major
scavenger cells for extracellular AS.39 To determine
whether phagocytosis of AS debris by microglia is a possi-
ble mechanism of AS clearance,39 we first used suspension
of AS debris prepared from U373 cells with hAS inclusions
as previously described10,14,35 (Figure 2A). Two hours after
incubation, AS debris were incorporated in BV2 immortal-
ized microglia (Figure 2A). Next, we found that phagocyto-sis of AS can be suppressed by functional blocking of TLR4
(Figure 2B). Finally, to confirm these findings, primary
TLR4/ and TLR4/ microglia was incubated for 1 hour
with recombinant AS. Forty percentage of the primary
TLR4/ microglia showed dotlike AS-positive profiles en-
gulfed in the cytoplasm, whereas only 2% of primary
TLR4/ microglia showed phagocytosed AS in their cyto-
plasm (Figure 2C).
As suggested by our in vitro results, the accumulation
of AS in the brains of AS,TLR4/ mice may be due to
disturbed microglial phagocytosis of AS. To confirm that
hAS is secreted from transgenic oligodendroglia into the
extracellular space, we measured by ELISA the release
of hAS in the supernatant of mixed glial cultures prepared
from PLP-AS mice and detected levels of 1.24 to 5.24
ng/mL of hAS. Next, in vivo phagocytosis of hAS by mi-
croglia was shown in brains of AS,TLR4/ mice (Figure
3A); however, it was not readily detectable in AS,TLR4/
mice (Figure 3B). This finding was confirmed by confocal
microscopy and three-dimensional analysis of confocal
images with Imaris x64 software and isosurface recon-
Figure 4. Electron microscopic analysis of the brains of AS,TLR4/ and
AS,TLR4/ mice. Microglia and macrophage cells were identified close to
the perivascular areas by their elongated nucleus with condensed chromatin
and abundant lysosomes and phagocytic organelles in the cytoplasm. In
AS,TLR4/ mice, microglia and macrophages showed abundant gold par-
ticles in association with phagosomes and lysosomes. In contrast, microglia
and macrophages of AS,TLR4/mice had fewer gold particles in phagocytic
cytoplasmic organelles as defined by the number of gold grains per microglia
and macrophage cell (n  125 for each). Original magnification, 5000 and
25,000, respectively. ***P  0.001.
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positive microglia (Figure 3C).
Ultrastructural analysis was further used to determine
the phagocytic activity of microglia in AS,TLR4/ and
AS,TLR4/ mice. Microglia and macrophage cells were
identified by their morphologic characteristics and close
proximity to perivascular areas. These cells usually have an
elongated nucleus with condensed chromatin and contain
abundant lysosomes and phagocytic organelles. Immuno-
gold labeling for AS in AS,TLR4/ and AS,TLR4/ mice
was localized in oligodendroglial cells in association with
the inner and outer mitochondrial membranes and cytoplas-
mic structures (data not shown). In the AS,TLR4/ mice
abundant gold particles were found in association with
phagosomes and lysosomes in microglia, whereas in
AS,TLR4/mice there were fewer gold particles in phago-
cytic cytoplasmic organelles (Figure 4).
Finally, to analyze the effect of TLR4 deficiency on AS
level in transgenic mice in vivo, hAS concentration in the
midbrain and forebrain was measured by ELISA and
showed a significant increase in AS,TLR4/ mice com-
pared with AS,TLR4/ mice (Figure 5).
AS,TLR4/ Mice Present with Increased
Levels of TNF- in the Midbrain Associated with
Proinflammatory Astroglial Response
Analysis of brain concentrations of several inflammatory
Figure 5. Effect of TLR4 ablation on AS brain levels. Four animals per group
were used to dissect the forebrain and midbrain and prepare lysates for
measurement of hAS protein concentration by ELISA. Two-way analysis of
variance (with factors genotype and area) with a post hoc Bonferroni test
showed a significant increase of hAS protein concentration in both the
forebrain and midbrain of AS,TLR4/ mice. ***P  0.001, ****P  0.0001.modulators was performed by fluorometric multiplexbead–based cytokine immunoassay. An unexpected re-
gion-specific increase of TNF- concentration in the mid-
brain was detected in AS,TLR4/ mice (Figure 6A).
However, other cytokines, including IL-6, IFN-, GM-CSF,
IL-10, and IL-1, did not show significant differences
between AS,TLR4/ and AS,TLR4/ mice in either the
midbrain or forebrain (Figure 6A). To define the cell
source of TNF- in the midbrain of AS,TLR4/ mice,
double immunofluorescence labeling was performed.
Predominant colocalization of GFAP and TNF- was ev-
idenced in the SNc of AS,TLR4/ mice (Figure 6B).
Discussion
Up-regulation of TLRs has been demonstrated in brains
with ASPs, such as PD, DLB, and MSA, highlighting in-
nate immunity as a novel therapeutic target in these dis-
orders.15,16 We show that TLR4 is an important mediator
of microglial phagocytosis of AS. We demonstrate dele-
terious effects of TLR4 ablation in a transgenic mouse
model of MSA.15,40–42 Motor impairment and loss of ni-
grostriatal dopaminergic neurons and fibers were signif-
icantly aggravated in TLR4-deficient mice with hAS over-
expression. This phenotype was associated with
increased AS accumulation throughout the brain, impli-
cating TLR4 signaling in the pathogenesis of ASPs. We
propose that TLR4 up-regulation in microglia is a natural
mechanism to boost the clearance of extracellular AS in
ASPs. Similar to previous studies that demonstrated AS
secretion from neuronal cells,43,44 we show that oligoden-
droglial cells overexpressing hAS are also able to secrete
Figure 6. Inflammatory mediation in ASPs in the absence of TLR4. A: Flow
cytomix analysis of IL-10, IFN-, IL-6, and GM-CSF in midbrain and forebrain
lysates demonstrated no significant differences between AS,TLR4/ and
AS,TLR4/ mice. However, strongly increased production of TNF- was
detected in the midbrain of AS,TLR4/ mice. For all analyses, n  6
(excluding IL-10 AS,TLR4/ mice, n  4). Data were analyzed by two-way
analysis of variance (with factors genotype and area) with a post hoc Bon-
ferroni test. Results are presented as mean SEM. B: Immunofluorescence in
/SNc of AS,TLR4 mice identified GFAP-positive astroglia (red) as the main
source of TNF- (green). Scale bar  10 m. ****P  0.0001.
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microglia. Liu et al45 previously described endocytosis of
fibrillar AS by microglia. The scavenger role of microglia
for extracellular AS has been proposed also by Lee et
al.39 We expand these findings by in vitro observations of
cytoplasmic AS incorporation in microglial cells in vitro.
Further, microglial phagocytosis of extracellular AS was
demonstrated in PLP-AS mice by immunofluorescent AS-
positive dotlike cytoplasmic deposits or AS-immunogold
labeling within microglial phagosomes. Functional block-
ing or knock down of TLR4 in microglia resulted in sup-
pression of AS phagocytosis in vitro, and TLR4 ablation in
vivo led to reduced phagocytosis by microglia associated
with accumulation of AS in the mouse brain. These results
confirm the role of TLR4-mediated clearance of extracel-
lular AS by microglia, the main cell type bearing TLR4 in
the brain; however, the exact mechanisms need further
elucidation. In summary, impaired TLR4-regulated AS
clearance appears to exacerbate neurodegeneration by
increasing AS accumulation, which is especially toxic to
nigral dopaminergic neurons,5,46 therefore contributing
to the pathogenesis of ASPs.
Parallel to the increased accumulation of AS that may
directly exert toxicity, we identified enhanced proinflam-
matory signaling with increased production of TNF- in
the midbrain of AS,TLR4/ mice. Double staining en-
abled us to define astroglia as the main source of TNF-
in SNc of AS,TLR4/ mice. The exact mechanism of this
proinflammatory response will need further elucidation. A
possible pathway may be the direct transfer of AS lead-
ing to an enhanced proinflammatory response by astro-
glia as recently suggested.47 The selectively increased
proinflammatory response in the midbrain of AS,TLR4/
mice in vivo may be related to the increased oxidative
stress milieu in SNc, associated with augmented cell
death of nigral dopaminergic neurons under the expo-
sure to higher concentrations of AS.48,49 The increased
levels of TNF- may further trigger the direct cell death of
dopaminergic neurons.50 Altogether these events con-
tribute to the vicious circle of progressive neurodegen-
eration in SNc in AS,TLR4/ mice.
The finding of enhanced nigral neuropathologic char-
acteristics in AS,TLR4/ mice is supported by our be-
havioral observations. The locomotor phenotype of mice
in the present study was analyzed applying two nigrostri-
atal pathway–dependent tests. The pole test is used to
assess basal ganglia–related movement disorders in
mice29,51–56 and involves several aspects of motor func-
tion, including movement initiation, balance, coordina-
tion, and bradykinesia, due to a hypodopaminergic state
rather than cerebellar abnormalities. Changes in rearing
behavior provide an early sign of basal ganglia dysfunc-
tion reflected in disturbed locomotor activity57 and
strengthen the finding that the motor phenotype ob-
served in AS,TLR4/ mice corresponds to the underly-
ing striatonigral pathologic features consistent with pre-
vious reports on mouse models of PD.55,56,58
We demonstrate now by in vitro and in vivo methods
that TLR4 is involved in the process of extracellular AS
uptake and clearance. On the basis of our current work,
we propose that TLR4 signaling participates in an endog-enous neuroprotective mechanism in ASPs, similar to
other protein-misfolding disorders. Recently, Spinner et
al59 reported increased disease-specific prion protein
PrPSc accumulation and reduced immune recognition
and response to PrPSc in TLR4-deficient mice compared
with wild-type animals, consistent with our current obser-
vations in a model of ASPs with TLR4 ablation. Further-
more, a similar mechanism involving TLRs appears to be
operative in the clearance of amyloid- in Alzheimer‘s
disease—another neurodegenerative disorder with a pri-
onlike pathogenesis.21–24,60
How plausible is it to target TLR4 responses in ASPs to
modify disease progression? Although administration of
TLR4 ligands may activate phagocytosis and clearance
of AS deposits and be related to beneficial effects, TLR4
agonist treatment could lead also to dangerous adverse
effects associated with the induction of high levels of
proinflammatory mediators.61–63 The proinflammatory
signaling induced by TLR4 agonists may be counter-
acted by co-application of specific antagonists to neu-
tralize the involved proinflammatory cytokines but en-
hance the phagocytic activity related to improved
clearance of the toxic protein species. This approach will
necessitate further preclinical investigations to define its
feasibility in ASPs.
In summary, in this study we show that misbalanced
TLR4 signaling may play a crucial role in ASP progres-
sion. The TLR4-dependent pathway represents an impor-
tant AS clearance mechanism. The present data empha-
size the importance of functional clearance mechanisms
related to a “healthy” microglial response in ASPs and sup-
port the hypothesis that progression of PD and related dis-
orders with AS pathologic characteristics may result from a
primary long-term impairment of microglia, reflecting age-
related dysfunction or genetic predisposition. The current
findings have significant implications for the development of
novel disease-modifying therapies for ASPs.
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